CRVS stock forecast, quote, news & analysis
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function... Show more
Why Corvus Pharmaceuticals (CRVS) Stock Is Down -27% in the Last 30 Days
Key Takeaways
- Corvus Pharmaceuticals (CRVS) shares declined roughly 27% over the last 30 days, falling from about $14.39 to approximately $10.44.
- The pullback follows a powerful multi-year rally, with the stock running from a 52-week low near $6.39 to a high of $26.95 earlier in 2026.
- The recent move reflects profit-taking and elevated short interest (about 26.5% of float) in a pre-revenue, clinical-stage biotech rather than a single negative catalyst.
- Over the last quarter, shares are down roughly 29%, consolidating after a January 2026 atopic dermatitis data readout that re-rated the stock.
- Analysts remain broadly constructive, with a consensus Buy rating and an average price target near $33.
Corvus Pharmaceuticals (CRVS) Company Overview and Market Position
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company develops immune-modulating therapies designed to precisely target proteins critical to immune cell maturation and function, with a focus on cancer and immune-mediated inflammatory diseases.
The lead product candidate is soquelitinib, an investigational oral small molecule that selectively inhibits ITK (interleukin-2-inducible T cell kinase). Soquelitinib is being evaluated in a registrational Phase 3 trial for relapsed/refractory peripheral T-cell lymphoma (PTCL), a Phase 2 trial for moderate-to-severe atopic dermatitis, and a Phase 1b trial for hidradenitis suppurativa, with a Phase 2 asthma trial planned. Corvus also holds earlier-stage candidates including ciforadenant (an A2A receptor antagonist) and mupadolimab (an anti-CD73 antibody).
As a development-stage company, Corvus generates no product revenue and funds operations primarily through equity financings and collaborations. Investors follow the stock for its clinical catalysts and the potential of selective ITK inhibition across oncology and immunology indications.
Corvus Pharmaceuticals (CRVS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, CRVS fell approximately 27%, declining from a close of $14.39 on September 4 to roughly $10.44. The decline was broad-based and steady rather than event-driven, with shares grinding lower through late September and early October.
The longer view shows a similar pattern. Over the last quarter, the stock has fallen roughly 29%, down from about $14.76 at the start of July. After peaking near $16.20 in mid-July, shares have trended steadily downward. This consolidation stands in contrast to the stock's dramatic longer-term performance: CRVS is still up significantly year-to-date and has delivered a multi-hundred-percent return over a three-year horizon, reflecting the powerful re-rating triggered by positive atopic dermatitis data earlier in 2026.
What Drove CRVS Stock Price in the Last 30 Days
The recent decline appears driven primarily by profit-taking and shifting sentiment in a high-beta, pre-revenue biotech, rather than by any single adverse event. After rising from roughly $6.39 to a 52-week high of $26.95, the stock entered a period of consolidation as traders and long-term holders locked in gains.
Elevated short interest has added to the pressure. With roughly 26.5% of the float sold short, the stock carries a sizable bearish overhang that can amplify downside moves during periods of weak momentum. On September 30, the company announced the initiation of a Phase 1b trial of soquelitinib in hidradenitis suppurativa, a small, single-arm safety study. While a positive pipeline step, it was widely viewed as an early proof-of-concept signal that does not materially change the company's core thesis, which hinges on the registrational Phase 3 PTCL trial. Corvus also disclosed a board leadership transition during the period, adding a degree of governance-related uncertainty.
What Drove CRVS Stock Performance Over the Last Quarter
The quarterly trend reflects a broader de-risking after an exceptional rally. The stock's surge was fueled by January 2026 data showing that 75% of patients in one atopic dermatitis cohort achieved an EASI-75 response, along with biomarker data suggesting the potential for drug-free remissions. That data set drove a re-rating across the year's first half.
Since mid-summer, however, the narrative has shifted from rapid appreciation to a "show-me" phase. The company reported second-quarter results in August confirming that enrollment in both the Phase 3 PTCL and Phase 2 atopic dermatitis trials remains on track, and published final Phase 1 data in Blood, but these updates lacked the near-term binary catalysts needed to sustain the earlier momentum. With no product revenue and clinical readouts still years away, investors have increasingly weighed valuation against a longer timeline to pivotal data.
Trending AI Robots
For traders seeking a systematic approach to names like CRVS, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading strategies. Tickeron provides hundreds of AI trading bots that monitor thousands of tickers across the market, yet only the top-performing and most relevant bots are surfaced in this section. These bots vary widely in strategy, timeframe, and performance metrics, allowing users to explore approaches that range from short-term momentum to longer-horizon trend following. For those looking to complement their own research with quantitative, data-driven signals, the Trending AI Robots page is a practical starting point.
CRVS Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the primary catalyst for Corvus is the registrational Phase 3 trial of soquelitinib in relapsed/refractory PTCL, though top-line data is not expected until late 2028. Nearer term, investors should monitor enrollment progress across the PTCL and atopic dermatitis studies, as well as initial signals from the hidradenitis suppurativa Phase 1b trial.
Quarterly financial results, expected around late October 2026, will provide updates on cash runway and operating expenses. Corvus reported roughly $215 million in cash and marketable securities, which management has indicated should fund operations into the second quarter of 2028, but spending trends and any future financing remain key considerations. Macroeconomic conditions, biotech-sector risk appetite, and movements in short interest could also influence share-price volatility. As always, clinical-stage investing carries meaningful binary risk, and outcomes remain uncertain.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CRVS sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for CRVS moved below the 200-day moving average on September 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRVS as a result. In 73 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
CRVS moved below its 50-day moving average on September 04, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRVS crossed bearishly below the 50-day moving average on September 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRVS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CRVS entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CRVS's RSI Indicator exited the oversold zone, 32 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRVS advanced for three days, in 203 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CRVS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating steady price growth. CRVS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRVS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron Valuation Rating of 72 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.431) is normal, around the industry mean (26.780). P/E Ratio (16.778) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of anticancer immuno-oncology drugs
Industry Biotechnology